VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

被引:93
作者
Enterlein, S
Warfield, KL
Swenson, DL
Stein, DA
Smith, JL
Gamble, CS
Kroeker, AD
Iversen, PL
Bavari, S
Mühlberger, E
机构
[1] Univ Marburg, Dept Virol, D-35043 Marburg, Germany
[2] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
[3] AVI BioPharma Inc, Corvallis, OR USA
关键词
D O I
10.1128/AAC.50.3.984-993.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
引用
收藏
页码:984 / 993
页数:10
相关论文
共 43 条
[1]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[2]   The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3 [J].
Basler, CF ;
Mikulasova, A ;
Martinez-Sobrido, L ;
Paragas, J ;
Mühlberger, E ;
Bray, M ;
Klenk, HD ;
Palese, P ;
García-Sastre, A .
JOURNAL OF VIROLOGY, 2003, 77 (14) :7945-7956
[3]   Interactions of Marburg virus nucleocapsid proteins [J].
Becker, S ;
Rinne, C ;
Hofsäss, U ;
Klenk, HD ;
Mühlberger, E .
VIROLOGY, 1998, 249 (02) :406-417
[4]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :651-661
[5]   The evolving field of biodefence: Therapeutic developments and diagnostics [J].
Burnett, JC ;
Henchal, EA ;
Schmaljohn, AL ;
Bavari, S .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) :281-297
[6]   Inhibition of flavivirus infections by antisense oligorners specifically suppressing viral translation and RNA replication [J].
Deas, TS ;
Binduga-Gajewska, I ;
Tilgner, M ;
Ren, P ;
Stein, DA ;
Moulton, HM ;
Iversen, PL ;
Kauffman, EB ;
Kramer, LD ;
Shi, PY .
JOURNAL OF VIROLOGY, 2005, 79 (08) :4599-4609
[7]  
Feldmann H, 1999, CURR TOP MICROBIOL, V235, P1
[8]  
Fisher-Hoch SP, 1999, CURR TOP MICROBIOL, V235, P117
[9]   Inhibition of Marburg virus protein expression and viral release by RNA interference [J].
Fowler, T ;
Bamberg, S ;
Möller, P ;
Klenk, HD ;
Meyer, TF ;
Becker, S ;
Rudel, T .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :1181-1188
[10]  
Geisbert Thomas W., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008300